Painful diabetic neuropathy

Bailliere's Best Practice and Research in Clinical Endocrinology and Metabolism

Volumn 13, Issue 2, 1999, Pages 295-308

  Benbow, S J ^a,b   MacFarlane, I A ^b  

^a HAIRMYRES HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

Anticonvulsants; Diabetic neuropathy; Pain; Tricyclic antidepressants

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANTICONVULSIVE AGENT; BACLOFEN; CALCITONIN; CAPSAICIN; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLONIDINE; DESIPRAMINE; DEXTROMETHORPHAN; FLUPHENAZINE; GABAPENTIN; GLUCOSE; IMIPRAMINE; LEVACECARNINE; LIDOCAINE; MECOBALAMIN; MEXILETINE; MIANSERIN; NORTRIPTYLINE; PARACETAMOL; PAROXETINE; PHENYTOIN; PYRIDOXINE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID;

ANTICHOLINERGIC EFFECT; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEUROPATHY; DRUG USE; ELECTROSTIMULATION THERAPY; FILM; HUMAN; META ANALYSIS; ORTHOSTATIC HYPOTENSION; PAIN; PATIENT CARE; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SPINAL CORD STIMULATION; TRANSCUTANEOUS NERVE STIMULATION;

EID: 0033502239     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1053/beem.1999.0021     Document Type: Article

References (152)

1. Benbow S, Wallymahmed M, MacFarlane I A. Diabetic peripheral neuropathy and quality of life. Quarterly Journal of Medicine. 91:1998;733-737.
2. Bowsher D. Neurogenic pain: diagnosis and treatment. Medical Times. 117:1989;21-26.
3. Merskey H. Classification of chronic pain. Pain. 3:1986;215-217.
4. Boulton A JM, Knight G, Drury J, Ward J D. The prevalence of symptomatic diabetic neuropathy in an insulin-treated population. Diabetes Care. 8:1985;125-128.
5. Watkins P J. Natural history of the diabetic neuropathies. Quarterly Journal of Medicine. 77:1990;1209-1218.
6. Partanen J, Niskanen L, Lehtinen J. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. New England Journal of Medicine. 333:1995;88-94.
7. Chan A W, MacFarlane I A, Bowsher D R. Chronic pain in patients with diabetes mellitus; comparison with a non-diabetic population. Pain Clinic. 3:1990;147-159.
8. Boulton A JM, Scarpello J HB, Armstrong W D, Ward J D. The natural history of painful diabetic neuropathy - a 4 year study. Postgraduate Medical Journal. 59:1983;556-559.
9. Archer A G, Watkins P J, Sharma A K, Payan J. The natural history of acute painful neuropathy in diabetes mellitus. Journal of Neurology, Neurosurgery and Psychiatry. 46:1983;491-499.
10. Young R J, Ewing D J, Clarke B F. Chronic and remitting painful diabetic neuropathy. Diabetes Care. 11:1988;34-40.
11. Mayne N. The short term prognosis of diabetic neuropathy. Diabetes. 17:1968;270-273.
12. Benbow S J, Chan A W, Bowsher D. A prospective study of painful symptoms, small-fibre function and peripheral vascular disease in chronic painful diabetic neuropathy. Diabetic Medicine. 11:1994;17-21.
13. Bischoff A. The natural course of diabetic neuropathy: a follow up. Hormone Metabolism Research. 9:1981;98-100.
14. Fry I K, Hardwick C, Scott G W. Diabetic neuropathy: a survey and follow up of 66 cases. Guys' Hospital Reports. 111:1962;113-129.
15. Jensen T S. Mechanisms of neuropathic pain. Campbell J N. Pain 1996 - an Updated Review. 1996;77-86 IASP Press, Seattle.
16. Benbow S J, Cossins L, MacFarlane I A. Painful diabetic neuropathy. Diabetic Medicine. 16:1999;632-644.
17. Nurmikko T J, Nash T P, Wiles J R. Control of chronic pain. British Medical Journal. 317:1998;1438-1441.
18. Boulton A JM, Ward J D. Diabetic neuropathies and pain. Clinical Endocrinology and Metabolism. 15:1986;917-931.
19. Thomas P K. Painful diabetic neuropathy: mechanism and treatment. Diabetes Nutrition and Metabolism. 7:1994;359-368.
20. Nurmikko T. Polyneuropathy pain. Campbell J N. Pain 1996 - an Updated Review. 1996;61-67 IASP Press, Seattle.
21. Scott J, Huskisson E C. Graphic representation of pain. Pain. 2:1976;175-184.
22. Sriwatanakul K, Kelvie W, Lasagna L. Studies with different types of visual analog scales for measurement of pain. Clinical Pharmacology and Therapeutics. 34:1983;234-239.
23. Melzack R, Torgerson W S. On the language of pain. Anaesthesiology. 34:1971;50-59.
24. Melzack R. The McGill pain questionnaire: major properties and scoring methods. Pain. 1:1975;277-299.
25. Masson E A, Hunt L, Gem J M, Boulton A JM. A novel approach to the diagnosis and assessment of symptomatic diabetic neuropathy. Pain. 38:1989;25-28.
26. Galer B S, Jensen M P. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology. 48:1997;332-338.
27. New England Journal of Medicine. 329:1993;977-986.
28. Boulton A JM, Drury J, Clarke B, Ward J D. Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care. 5:1982;386-390.
29. Samanta A, Burden A C. Rapid improvement in pain of diabetic neuropathy using an open-loop intravenous insulin infusion system. Practical Diabetes. 2:1985;22-23.
30. Ziegler D, Dannehl K, Wiefels K, Gries F A. Differential effects of near-normoglycaemia for 4 years on somatic nerve dysfunction and heart rate variation in type 1 diabetic patients. Diabetic Medicine. 9:1992;622-629.
31. Bertelsman F W, Heimans J J, Van Rooy J CGM. Peripheral nerve function in patients with painful diabetic neuropathy treated with continuous subcutaneous insulin infusion. Journal of Neurology, Neurosurgery and Psychiatry. 50:1987;1337-1341.
32. Ward J, Armstrong W, Preston E. Pain in the diabetic leg: a trial of aspirin and dipyridamole in diabetic neuropathy. Pharmatherapeutica. 2:1981;642-647.
33. Vinik A I, Holland M T, Le Beau J M. Diabetic neuropathies. Diabetes Care. 15:1992;1926-1975.
34. Young R J, Clarke B F. Pain relief in diabetic neuropathy: the effectiveness of imipramine and related drugs. Diabetic Medicine. 2:1985;363-366.
35. Cohen K L, Harris S. Efficacy and safety of nonsteroidal anti-inflammatory drugs in the therapy of diabetic neuropathy. Archives of Internal Medicine. 147:1987;1442-1444.
36. Turkington R W. Depression masquerading as diabetic neuropathy. Journal of the American Medical Association. 243:1980;1147-1150.
37. Max M B, Culnane M, Schafer S C. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology. 37:1987;589-596.
38. Davis J L, Lewis S B, Gerich J E. Peripheral diabetic neuropathy treated with amitriptyline and fluphenazine. Journal of the American Medical Association. 238:1977;2291-2292.
39. Kvinesdal B, Molin J, Froland A, Gram L F. Imipramine treatment of painful diabetic neuropathy. Journal of the American Medical Association. 251:1984;1727-1730.
40. Sindrup S H, Gram L F, Brosen K. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain. 42:1990;135-144.
41. Max M B, Kishore-Kumar R, Schafer S C. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain. 45:1991;3-9.
42. Sindrup S H. Antidepressants in the treatment of diabetic neuropathy symptoms. Danish Medical Bulletin. 41:1994;66-78.
43. Sindrup S H, Gram L F, Skjold T. Concentration-response relationship in imipramine treatment of diabetic neuropathy symptoms. Clinical Pharmacology and Therapeutics. 47:1990;509-515.
44. Battla H, Silverblatt C W. Clinical trial of amitriptyline and fluphenazine in diabetic peripheral neuropathy. Southern Medical Journal. 74:1981;417-418.
45. Mitas J A, Mosley C A, Drager A M. Diabetic neuropathic pain: control by amitriptyline and fluphenazine in renal insufficiency. Southern Medical Journal. 76:1983;462-463.
46. Khurana R C. Treatment of painful diabetic neuropathy with trazodone. Journal of the American Medical Association. 250:1983;1392.
47. Sindrup S H, Ejlertsen B, Froland A. Imipramine treatment in diabetic neuropathy: relief of subjective symptoms without changes in peripheral and autonomic nerve function. European Journal of Clinical Pharmacology. 37:1989;151-153.
48. Sindrup S H, Tuxen C, Gram L F. Lack of effect of mianserin on the symptoms of diabetic neuropathy. European Journal of Clinical Pharmacology. 43:1992;251-255.
49. Max M B, Lynch S A, Muir J. Effects of desipramine, amitriptyline and fluoxetine on pain in diabetic neuropathy. New England Journal of Medicine. 326:1992;1250-1256.
50. Sindrup S H, Skjold T, Grodum E. Clomipramine versus desipramine versus placebo in the treatment of diabetic neuropathy symptoms. British Journal of Clinical Pharmacology. 30:1990;683-691.
51. Blackwell B. Side effects of antidepressant drugs. Psychiatry Update. 6:1987;724-745.
52. Shader R I, Kennedy J S. Biological treatment. Kaplan H I, Sadock B J. Comprehensive Textbook of Psychiatry. 1989;2037-2049 Williams & Wilkins, Baltimore.
53. Gomez-Perez F J, Rull J A, Dies H. Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy. A double-blind cross-over study. Pain. 23:1985;395-400.
54. Roose S P, Glassman A H, Siris S. Comparison of imipramine and nortriptyline-induced orthostatic hypotension: a meaningful difference. Journal of Clinical Psychopharmacology. 1:1981;316-319.
55. Mendel C M, Klein R F, Chappell D A. A trial of amitriptyline and fluphenazine in the treatment of painful diabetic neuropathy. Journal of the American Medical Association. 255:1986;637-639.
56. Gade G N, Hofeldt F D, Treice G L. Diabetic neuropathic cachexia - beneficial response to combination therapy with amitriptyline and fluphenazine. Journal of the American Medical Association. 243:1980;1160-1161.
57. Gomez-Perez F J, Choza R, Rios J M. Nortriptyline-fluphenazine vs. carbamazepine in symptomatic treatment of diabetic neuropathy. Archives of Medical Research. 27:1996;525-529.
58. Kane J M, Smith J M. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Archives of General Psychiatry. 39:1982;473-481.
59. Sindrup S H, Bjerre U, Dejgaard A. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clinical Pharmacology and Therapeutics. 52:1992;547-552.
60. McQuay J H, Tramer M, Nye B A. A systematic review of antidepressants in neuropathic pain. Pain. 68:1996;217-227.
61. Rull J A, Quibrera R, Gonzalez-Millan H, Lozano Castaneda O. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine: double-blind cross-over trial. Diabetologia. 5:1969;215-218.
62. Wilton T D. Tegretol in the treatment of diabetic neuropathy. South African Medical Journal. 48:1974;869-872.
63. Chakrabarti A K, Samantaray S K. Diabetic peripheral neuropathy: nerve conduction studies before, during and after carbamazepine. Australian and New Zealand Journal of Medicine. 6:1976;565-568.
64. Badran A M, Aly M A, Sous E S. A clinical trial of carbamazepine in the symptomatic treatment of diabetic peripheral neuropathy. Journal of the Egyptian Medical Association. 58:1975;627-631.
65. Ellenberg M. Treatment of diabetic neuropathy with diphenylhydantoin. New York State Journal of Medicine. 68:1968;2653-2655.
66. Chadda V S, Mathur M S. Double-blind study of the effects of diphenylhydantoin sodium on diabetic neuropathy. Journal of the Association of Physicians of India. 26:1978;403-406.
67. Saudek C D, Werns M S, Reidenberg M M. Phenytoin in the treatment of diabetic symmetrical polyneuropathy. Clinical Pharmacology and Therapeutics. 2:1977;196-199.
68. Bowsher D. Neurogenic pain syndromes and their management. British Medical Bulletin. 47:1991;644-666.
69. McQuay H, Carroll D, Jadad A R. Anticonvulsant drugs for management of pain: a systematic review. British Medical Journal. 311:1995;1047-1052.
70. Backonja M, Beydoun A, Edwards K R. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. Journal of the American Medical Association. 280:1998;1831-1836.
71. Boas R A, Covino B G, Shahnarian A. Analgesic responses to intravenous lignocaine. British Journal of Anaesthesia. 54:1982;501-505.
72. Edwards W T, Habib F, Burney R G, Begin G. Intravenous lidocaine in the management of various chronic pain states. A review of 211 cases. Regional Anaesthesia. 10:1985;1-6.
73. Kastrup J, Petersen P, Dejgaard A. Intravenous lidocaine infusion - a new treatment of chronic painful diabetic neuropathy. Pain. 28:1987;69-75.
74. Dejgaard A, Petersen P, Kastrup J. Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet. i:1988;9-11.
75. Stracke H, Meyer U E, Schumacher H E, Federlin K. Mexiletine in the treatment of diabetic neuropathy. Diabetes Care. 15:1992;1550-1555.
76. Oskarsson P, Ljunggren J G, Lins P E. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. Diabetes Care. 20:1997;1594-1597.
77. Wright J M, Oki J C, Graves L. Mexiletine in the symptomatic treatment of diabetic peripheral neuropathy. Annals of Pharmacology. 31:1997;29-34.
78. Buck S H, Burks T F. The neuropharmacology of capsaicin: review of some recent observations. Pharmacology Review. 38:1986;179-226.
79. Lynn B. Capsaicin: actions on nociceptive C-fibres and therapeutic potential. Pain. 41:1990;61-69.
80. Fitzgerald M. Capsaicin and sensory neurones - a review. Pain. 15:1983;109-130.
81. Ross D R, Varipapa R J. Treatment of painful diabetic neuropathy with topical capsaicin. New England Journal of Medicine. 321:1989;474-475.
82. Archives of Internal Medicine. 151:1991;2225-2229.
83. Tandan R, Lewis G A, Krusinski P B. Topical capsaicin in painful diabetic neuropathy (controlled study with long-term follow-up). Diabetes Care. 15:1992;8-14.
84. Scheffler N M, Sheitel P L, Lipton M N. Treatment of painful diabetic neuropathy with capsaicin 0·075%. Journal of the American Podiatric Medical Association. 81:1991;288-293.
85. Chad D A, Aronin N, Lundstrom R. Does capsaicin relieve the pain of diabetic neuropathy? Pain. 42:1990;387-388.
86. Veves A, Boulton A JM. Measuring subjective symptoms. Diabetes Care. 15:1992;1434.
87. Zhang W Y, Po A LW. The effectiveness of topically applied capsaicin: a meta-analysis. European Journal of Clinical Pharmacology. 46:1994;517-522.
88. Biesbroek R, Bril V, Hollander P. A double-blind comparison of topical capsaicin and oral amitriptyline in painful diabetic neuropathy. Advances in Therapy. 12:1995;111-120.
89. Levy D M, Abraham R R, Tomlinson D R. Topical capsaicin in the treatment of painful diabetic neuropathy. New England Journal of Medicine. 324:1991;776-777.
90. Tandan R, Lewis G A, Badger G B, Fries T J. Topical capsaicin in painful diabetic neuropathy (effect on sensory function). Diabetes Care. 15:1992;15-18.
91. Simpson B A. Spinal cord stimulation. Pain Review. 1:1994;199-230.
92. Kumar K, Toth C, Nath R K. Spinal cord stimulation for chronic pain in peripheral neuropathy. Surgical Neurology. 46:1996;363-369.
93. Tesfaye S, Watt J, Benbow S J. Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy. Lancet. 348:1996;1698-1701.
94. Benbow S J, Watt J, Miles J. Electrical spinal cord stimulation in painful diabetic neuropathy: long-term efficacy and safety. Diabetic Medicine. 15:1998;S11.
95. Watkins E S, Koeze T H. Spinal cord stimulation and pain relief. British Medical Journal. 307:1993;462.
96. Meyerson B A. Mechanisms of spinal cord stimulation as pain treatment. Campbell J N. Pain 1996 - an Updated Review. 1996;207-215 IASP Press, Seattle.
97. Thorsteinsson G, Stonnington H H, Stillwell G K, Elveback L R. Transcutaneous electrical stimulation: a double-blind trial of its efficacy for pain. Archives of Physical Medicine and Rehabilitation. 58:1977;8-13.
98. Kumar D, Marshall H J. Diabetic peripheral neuropathy: amelioration of pain with transcutaneous electrostimulation. Diabetes Care. 20:1997;1702-1705.
99. Foster A VM, Eaton C, McConville D O, Edmonds M E. Application of OpSite film: a new and effective treatment of painful diabetic neuropathy. Diabetic Medicine. 11:1994;768-772.
100. Masson E A, Boulton A JM. Aldose reductase inhibitors in the treatment of diabetic neuropathy. Drugs. 39:1990;190-202.
101. Pfeifer M A, Schumer M P, Gelber D A. Aldose reductase inhibitors: the end of an era or the need for different trial designs? Diabetes. 46:1997;S82-S89.
102. Watkins P J. Treatment for diabetic neuropathy. Diabetic Medicine. 13:1996;1007-1008.
103. Nicolucci A, Carinci F, Cavaliere D. A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. Diabetic Medicine. 13:1996;1017-1026.
104. Tesfaye S, Price D E. Therapeutic approaches in diabetic neuropathy and neuropathic pain. Boulton A JM. Diabetic Neuropathy. 1997;159-181 Marius Press, Carnforth.
105. Young R J, Ewing D J, Clarke B F. A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic painful neuropathy. Diabetes. 32:1983;938-942.
106. Boulton A JM, Levin S, Comstock J. A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia. 33:1990;431-437.
107. Goto Y, Hotta N, Shigeta Y. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. Biomedical Pharmacotherapeutics. 49:1995;269-277.
108. Santiago J V, Sonksen P H, Boulton A JM. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. Journal of Diabetes and its Complications. 7:1993;170-178.
109. Hotta N, Sakamoto N, Shigeta Y. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicentre study. Journal of Diabetes and its Complications. 10:1996;168-172.
110. Horrobin D F. The roles of essential fatty acids in the development of diabetic neuropathy and other complications of diabetes mellitus. Prostaglandins, Leukotrienes and Essential Fatty Acids. 31:1988;181-197.
111. Cameron N E, Cotter M A. Potential therapeutic approaches to the treatment or prevention of diabetic neuropathy: evidence from experimental studies. Diabetic Medicine. 10:1993;593-605.
112. Jamal G A, Carmichael H. The effect of gamma-linolenic acid on human diabetic peripheral neuropathy: a double-blind placebo-controlled trial. Diabetic Medicine. 7:1990;319-323.
113. Benbow, S, J, The Natural History, Pathophysiology and Treatment of Diabetic Neuropathy, 1995.
114. Fedele D, Crepaldi G, Battistin L. Multicentre trial on gangliosides in diabetic peripheral neuropathy. Advances in Experimental Medicine and Biology. 174:1984;601-606.
115. Liniger C, Pernet A, Moody J F, Assal J Ph. Effect of gangliosides on diabetic peripheral neuropathy. Diabetes Research and Clinical Practice. 7:1989;251-258.
116. Lingetti M, Coto V, Rengo F. Gangliosides in the treatment of diabetic neuropathy: a randomised, double-blind, placebo-controlled, dose-finding study. Diabetes, Nutrition and Metabolism. 5:1992;275-282.
117. Horowitz S H. Ganglioside therapy in diabetic neuropathy. Muscle and Nerve. 9:1986;531-536.
118. Crepaldi G, Fedele D, Tiengo A. Ganglioside treatment in diabetic peripheral neuropathy: a multicentre trial. Acta Diabetica Latina. 20:1983;265-276.
119. Naarden A, Davidson J, Harris L. Treatment of painful diabetic polyneuropathy with mixed gangliosides. Advances in Experimental Medicine and Biology. 174:1984;581-592.
120. Hallett M, Flood T, Slater N, Dambrosia J. Trial of ganglioside therapy for diabetic neuropathy. Muscle and Nerve. 10:1987;822-825.
121. Low P A, Nickander K K. Oxygen free radical effects in sciatic nerve in experimental diabetes. Diabetes. 40:1991;873-877.
122. Ziegler D, Hanefeld M, Ruhnau K J. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. Diabetologia. 38:1995;1425-1433.
123. Sachse G, Wilms B. Efficacy of thioctic acid in the therapy of peripheral diabetic neuropathy. Gries F A, Freund H J, Rabe F, Berger H. Aspects of Autonomic Neuropathy in Diabetes. Hormone Metabolism Research. 1980;105-108.
124. Nelsen K A, Park K M, Robinovitz E. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology. 48:1997;1212-1218.
125. Tan Y-M, Croese J. Clonidine and diabetic patients with leg pains. Annals of Internal Medicine. 105:1986;633-634.
126. Ziegler D, Lynch S A, Muir J. Transdermal clonidine versus placebo in painful diabetic neuropathy. Pain. 48:1992;403-408.
127. Cohen K L, Lucibello F E, Chomiak M A. Lack of effect of clonidine and pentoxifylline in short-term therapy of diabetic peripheral neuropathy. Diabetes Care. 13:1990;1074-1077.
128. Byas-Smith M G, Max M B, Muir J, Kingman A. Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage 'enriched enrolment' design. Pain. 60:1995;267-274.
129. Arner S, Meyerson B A. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain. 33:1988;11-23.
130. Portenoy R K, Foley K M, Inturrisi C E. The nature of opioid responsiveness and its implication for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain. 43:1990;273-286.
131. Dubner R. A call for more science, not more rhetoric, regarding opioids and neuropathic pain. Pain. 47:1991;1-2.
132. Lee C R, McTavish D, Sorkin E M. Tramadol: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in various acute and chronic pain states. Drugs. 46:1993;313-340.
133. Harati Y, Gooch C, Swenson M. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 50:1998;1842-1846.
134. Quatraro A, Minei A, De Rosa N, Giugliano D. Calcitonin in painful diabetic neuropathy. Lancet. 339:1992;746-747.
135. Zieleniewski W. Calcitonin nasal spray for painful diabetic neuropathy. Lancet. 336:1990;449.
136. Terrence C F, Fromm G H, Tenicela R. Baclofen as an analgesic in chronic peripheral nerve disease. European Neurology. 24:1985;380-385.
137. Ide H, Fujiya S, Asanuma Y. Clinical usefulness of intrathecal injection of methylcobalamin in patients with diabetic neuropathy. Clinical Therapeutics. 9:1987;183-192.
138. Levin E R, Hanscom T A, Fisher M. The influence of pyridoxine in diabetic peripheral neuropathy. Diabetes Care. 4:1981;606-609.
139. McCann V J, Davis R E. Pyridoxine and diabetic neuropathy - a double-blind controlled study. Diabetes Care. 6:1983;102-103.
140. Quatraro A, Roca P, Donzella C. Acetyl-L-carnitine for symptomatic diabetic neuropathy. Diabetologia. 38:1995;123.
141. Heimans J J, Drukarch B, Matthaei I. Cyclandelate in diabetic neuropathy. A double-blind, placebo-controlled, randomised, cross-over study. Acta Neurologica Scandinavia. 84:1991;483-486.
142. Cohen K L, Harris S. Pentoxifylline and diabetic neuropathy. Annals of Internal Medicine. 107:1987;600-601.
143. Cohen S M, Matthews T. Pentoxifylline in the treatment of distal diabetic neuropathy. Angiology. 42:1991;741-746.
144. Shindo H, Tawata M, Aida K, Onaya T. Clinical efficacy of a stable prostacyclin analog, iloprost, in diabetic neuropathy. Prostaglandins. 41:1991;85-96.
145. Chan A W, Williams G, MacFarlane I A, Bowsher D. Octreotide, a long-acting somatostin analogue, in diabetic neuropathic pain. Hormone Research. 36:1991;86-87.
146. Wieman T J, Patel V J. Treatment of hyperesthetic neuropathic pain in diabetics. Annals of Surgery. 221:1995;660-665.
147. Armstrong D G, Fleischli J G, Lavery L A, Gilham K A. Is electrical stimulation effective in reducing neuropathic pain in patients with diabetes? Foot and Ankle Surgery. 36:1997;260-263.
148. Benbow S J, Williams G, MacFarlane I A. Smoking habits and painful diabetic neuropathy. Journal of Diabetes and its Complications. 11:1997;334-337.
149. Ertas M, Sagduyu A, Arac N. Use of levodopa to relieve pain from painful symmetrical diabetic polyneuropathy. Pain. 75:1998;257-259.
150. Pfeifer M A, Ross D R, Schrage J P. A highly successful and novel model for treatment of chronic painful diabetic peripheral neuropathy. Diabetes Care. 16:1993;1103-1115.
151. Asbury A K, Fields H L. Pain due to peripheral nerve damage: an hypothesis. Neurology. 34:1984;1587-1590.
152. Davies H TO, Crombie I K, Macrae W A. Why use a pain clinic? Management of neurogenic pain before and after referral. Journal of the Royal Society of Medicine. 87:1994;382-385.